STRATEC SE : Preliminary results – Bottom-line trough to come in 2023
>Weak finish of a weak year - Stratec reported preliminary FY 2022 revenues of € 274.6m (-4.4% y-o-y, -8.3% in constant currencies), which were 1.8% below our forecast of € 279.7m. The guidance for sales decline in constant currencies was at a range of 5.0% to 8.0%. The corresponding miss to our Q4 revenues forecast was 7% and 6% to Visible Alpha consensus. Despite no further details provided, we identify continued supply constraints as the major reason for the weake...STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.